How could emerging adjuvant and neoadjuvant immunotherapy strategies transform the treatment paradigm for genitourinary (GU) cancers?
This educational series examines the current and emerging roles of immunotherapy and antibody-drug conjugates in non-muscle-invasive and muscle-invasive bladder cancer. The series also dives into strategies for selecting and sequencing immunotherapies for patients with advanced renal cell carcinoma.
Provided by:
In Partnership with:
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Emerging targeted therapy combination strategies in genitourinary malignancies
Emerging targeted therapy combination strategies in genitourinary malignancies
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer
Emerging immunotherapy combination strategies in genitourinary malignancies
Emerging immunotherapy combination strategies in genitourinary malignancies
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
